ELV — Elevance Health Inc.

Market sentiment is bullish after Q3 2026 adjusted EPS of $6.99 beat consensus, the medical loss ratio improved 70 bps YoY to 90.6%, and management raised 2026 adjusted EPS guidance to at least $29.00 from about $27.00. As of 2026-10-21, ELV was at $443.31, up 4.24% in a week and 35.97% over six months, near its 52-week high of $448.71; the main offset is an overbought RSI of 75.42.

Revenue growth has been positive but low-single-digit: Q3 2026 revenue of $51.429B rose 1.4% YoY from $50.711B, Q2 2026 rose 1.4%, and Q1 2026 rose 2.6%. The clear trend is margin compression through 2025 followed by an inflection: operating margin fell from 7.5% in Q1 2024 to 1.2% in Q4 2025, then recovered to 5.3% in Q1 2026, 4.1% in Q2, and 4.2% in Q3; Q3 2026 operating income rose 22.5% YoY to $2.152B and EPS rose 17.9% to $6.27. This looks like a recent stabilization/partial recovery rather than a fully proven structural uptrend; TTM net income is still down YoY, so Q4 and 2027 guidance need to confirm it.

Using the supplied $443.31 price and $23.26 TTM EPS, the calculated P/E is about 19.1x, not the 1.9x in the FMP block, which is internally inconsistent. On management's at-least $29.00 2026 adjusted EPS, forward P/E is roughly 15.3x versus a 5-year average P/E of 17.21x, so it is modestly cheap on adjusted forward earnings. P/S is 0.48x versus a 5-year average of 0.62x. The FMP PEG of 0.002 is not usable; with low-single-digit revenue growth and a just-beginning margin recovery, the honest read is fair value, not a deep discount.

The share price already capitalizes much of the earnings rebound: at $443.31 as of 2026-10-21, investors are paying ~15.3x the $29.00 2026 adjusted EPS guide, and the analyst consensus target of $448.73 is almost exactly where the stock trades. If 2027 delivers management's 12% adjusted EPS growth off that baseline (~$32.50), today's price is not expensive; if margin recovery stalls, there is little valuation cushion. This is a 'show-me' setup rather than a deeply undervalued turnaround.

As of 2026-10-21, RSI-14 was 75.42 (overbought), price was 8.84% above its 20-day SMA, 9.77% above its 50-day SMA, and 20.46% above its 200-day SMA, with the stock near the 52-week high of $448.71. The trend is strongly up, but the entry timing is poor for new money; a pullback toward the moving averages would offer a better risk/reward.

• Medical cost trend and utilization in Medicare Advantage, Medicaid, and ACA are the key swing factor; Q3 2026's 90.6% medical loss ratio showed improvement, but cost re-acceleration would hit margins quickly.
• Government reimbursement and Medicaid redeterminations: state and federal rate updates can pressure revenue and margins in Elevance's Blues plans.
• Medicare Advantage rate environment and annual enrollment period: regulatory rate notices and enrollment positioning drive 2027 growth.
• Interest rates affect investment income on insurance float; higher-for-longer rates help, falling rates lower that tailwind.
• Defensive healthcare sector rotation and regulatory headline risk around managed care can drive multiple expansion or compression independent of fundamentals.

• Q4 2026 earnings and 2027 guidance (estimated late January 2027, not officially confirmed) must confirm the Q3 margin inflection.
• Medicare Advantage and ACA annual enrollment period metrics for 2027.
• State Medicaid rate updates and redetermination outcomes.
• Carelon services segment execution and non-insurance revenue growth.

• Medical loss ratio re-acceleration; Q3 improvement may not persist.
• Regulatory and reimbursement pressure in Medicare Advantage, Medicaid, and ACA.
• Execution risk in Carelon and integration of health services.
• Valuation and technical risk: after a 36% six-month run and RSI near 75, multiple compression or profit-taking is a near-term risk.

Elevance is a solid, cash-generative managed-care franchise whose margin trajectory has finally turned in Q3 2026, and forward adjusted EPS guidance of at least $29.00 leaves the stock roughly fairly valued at $443.31. The problem is timing: the stock has already run 36% in six months, trades near the consensus target, and is technically overbought, so the risk/reward is balanced rather than compelling. A better entry would come on a pullback or after another quarter confirms the margin recovery.

Applied a 16.0x P/E multiple to management's 2026 adjusted EPS guidance of at least $29.00, a modest discount to the stock's 5-year average P/E of 17.21x to reflect low-single-digit revenue growth and regulatory risk; this yields $464 per share.